Ensysce Biosciences (ENSC) Free Cash Flow Growth (1y) (2019 - 2025)
Ensysce Biosciences (ENSC) Free Cash Flow Growth (1y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 9.25% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -38.10% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 38.94% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 96.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 152.82% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.34% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 58.53% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 31.57% |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -82.90% |
| Jun 30, 2025 | -17.19% |
| Mar 31, 2025 | 49.91% |
| Dec 31, 2024 | 57.59% |
| Sep 30, 2024 | 54.91% |
| Jun 30, 2024 | 25.69% |
| Mar 31, 2024 | 5.50% |
| Dec 31, 2023 | 45.33% |
| Sep 30, 2023 | 66.30% |
| Jun 30, 2023 | 30.00% |
| Mar 31, 2023 | -4.94% |
| Dec 31, 2022 | 12.53% |
| Sep 30, 2022 | -75.54% |
| Jun 30, 2022 | -3,256.08% |
| Mar 31, 2022 | -564.61% |
| Dec 31, 2021 | -605.77% |
| Sep 30, 2021 | -2,401.38% |
| Jun 30, 2021 | 59.44% |
| Mar 31, 2021 | -120.64% |
| Dec 31, 2020 | -25.39% |